Abstract The concept of a precise region in which to find the lymph nodes that drain the lymph directly from the primary tumor site can be traced back to a century ago to the observations of Jamieson and Dobson who described how cancer cells spread from cancer of the stomach in a single lymph node, which they called the ''primary gland''. However, Cabanas was the first in 1977 to realize the importance of this concept in clinical studies following lymphography performed in patients with penile cancer. Thanks to Morton's studies on melanoma in 1992, we began to understand the potential impact of the sentinel lymph node (SN) on the surgical treatment of this type of cancer. The use of a vital dye (blue dye) administered subdermally in the region surrounding the melanoma lesion led to the identification of the sentinel node, and the vital dye technique was subsequently applied to other types of solid tumors, e.g. breast, vulva. However, difficulties in using this technique in anatomical regions with deep lymphatic vessels, e.g. axilla, led to the development of lymphoscintigraphy, started by Alex and Krag in 1993 on melanoma and breast cancer and optimized by our group at European Institute of Oncology (IEO) in Milan in 1996. Today, lymphoscintigraphy is still considered as the most reliable method for the detection of the SN. In 1996, a new method for the localization of non-palpable breast lesion called radioguided occult lesion localization (ROLL) was also developed at IEO. Retrospective and prospective studies have since shown that the ROLL procedure permits the easy and accurate surgical removal of non-palpable breast lesions, overcoming the limitations of previous techniques such as the wire-guided localization. The purpose of this paper is to describe the evolution of SN biopsy and radioguided surgery in the management of breast cancer. We also include a review of the literature on the clinical scenarios in which SN biopsy in breast cancer is currently used, with particular reference to controversies and future prospects.
Introduction
The sentinel lymph node (SN) technique and radioguided occult lesion localization (ROLL) of non-palpable tumors have changed the way we evaluate and treat early breast cancer, reducing the morbidity and improving the quality of life of patients. The concept of ''sentinel lymph node'' is intimately linked to the notion that, in the majority of patients, the metastatic spread of cancer through the lymphatic system follows a unidirectional, orderly and predictable pattern [1, 2] . On the basis of this assumption, the histological evaluation of the ''sentinel node'', i.e. the first lymph node that drains the lymph directly from the primary tumor, enables us to exclude the presence of malignant cells in other lymph nodes. Therefore, the status of the SN is capable of accurately predicting the pathological state of the subsequent regional lymph node stations. Cabanas was the first to understand the importance of this concept in 1977 in clinical studies performed on patients with penile cancer [3] . He not only managed to locate the SN (which he mistakenly believed to be located in a fixed anatomic site), but also observed a correlation between disease status and lymph node involvement, concluding that if the SN biopsy was negative, there would be no need to perform further surgical treatments.
During the 1990s, the potential impact of SN on the surgical treatment of cancer was further demonstrated in the clinical setting [4, 5] by the use of a vital dye (blue dye) administered subdermally in the region surrounding the lesion. However, the low success rate of this method led to the development of lymphoscintigraphy, subsequently acknowledged as the most reliable method for SN detection. Alex and Krag [6] were the first to publish results on lymphoscintigraphy in melanoma and breast cancer in 1993, after which the technique was optimized by our group at the European Institute of Oncology (IEO) in Milan in 1996-1998 [7, 8] . Since then, the procedure has been used in thousands of breast cancer patients throughout Europe. The first randomized trial comparing total axillary dissection with SN biopsy was performed by Veronesi and co-workers [9] on patients with breast cancers \2 cm in size. After preliminary results favoring SN biopsy were made known, new patients refused to be randomized and the study was forced to close with a recruitment of 516 patients (257 in the SN biopsy ? total axillary dissection arm vs. 259 in the SN biopsy only arm). Of the 257 patients in the axillary dissection group, 32.3 % of patients had a positive SN and 174 had a negative sentinel node (67.7 %). Of the 259 patients in the SN group, 92 had a positive SN (35.5 %), and 167 had a negative SN (64.5 %). The IEO results were further confirmed by those of the NSABP B-32 study [10, 11] , i.e. sentinel lymph node biopsy accurately predicted axillary status in 96.9 % of patients, with a falsenegative rate of 8.8 %. Moreover, post-operative morbidities were much less frequent in the sentinel node group. In 1996, in addition to the SN study for the optimization of the lymphoscintigraphy technique, a new method for the localization of non-palpable breast lesions called ROLL (radioguided occult lesion localization) was also developed by our group [12, 13] .
Wire-guided localization (WGL) has been the standard technique for many years to localize non-palpable lesions [14] : the surgeon uses a thin, hooked wire inserted under ultrasound or stereotactic guidance into the lesion to identify and remove it. However, numerous studies [15, 16] have reported a high rate of positive margins after wire localization (between 14 and 47 %) resulting in the need for re-operation or in a greater incidence of local recurrence.
In the ROLL technique, a radioactive tracer ( 99m TcMAA) is injected into the tumor under stereotactic or ultrasound guidance the day before surgery. A handheld gamma probe similar to that of SN biopsy is used to guide intra-operative lesion identification and surgical resection [12] . Several publications have suggested that this technique has led to decreased positive margin rates, a lower incidence of re-operation and more accurate surgical excision [17] [18] [19] [20] [21] .
In the present article, we report some of the most important developments made in the fields of SN biopsy and ROLL technique in breast cancer.
SN methodological aspects
Despite its widespread use, there is still no general consensus on the correct methodology of the SN biopsy procedure and numerous open questions remain to be resolved, e.g. kind of tracer to use, route of injection, or correct imaging technique (static, SPECT or SPECT/CT).
Radiotracers
The radiopharmaceutical used for SN biopsy must meet the following requirements:
1. It must permit the visualization of the lymphatic channels leading from the site of administration to the corresponding lymph node. 2. It must be retained in the first lymph node(s) encountered along such lymphatic pathways. Intranodal retention is due to the macrophages lining the sinusoid spaces of lymph nodes whose main function is to clear the affluent lymph of particulate matters through an active, saturable phagocytosis process [7, 22] .
The efficient uptake of radiolabelled particles in lymph nodes is dependent on the size of the particles, the surface charge and on a preliminary reaction of opsonization that activates membrane receptors on the macrophages and consequently phagocytosis of the radiocompound [7, [22] [23] [24] [25] [26] [27] . These characteristics are shared by different formulations, both inorganic ( 198 Au-colloid, 99m Tc-antimony sulfide, 99m Tc-sulfur colloid, 99m Tc-stannous fluoride, 99m Tc-rhenium sulfide) and organic (micro-or nanocolloid human albumin). After interstitial administration, the colloidal particles pass into the lymphatic circulation with a speed that is inversely proportional to particle size [25, 28] .
In our experience, the ideal tracer is composed of particles between 100 and 200 nm in size to obtain the best compromise between speed of drainage and accumulation in the sentinel node. In fact, colloidal tracer particles smaller than 50 nm drain rapidly into the lymphatic vessels but also pass easily into second-and third-level lymph nodes. On the other hand, tracers composed of particles [300 nm do not drain easily into the lymphatic system, making it difficult to visualize the SN. In our first series of 240 consecutive patients, the mean number of lymph nodes visualized using radiocolloid particles ranging in size between 15 and 50 nm was 2.1 (SD 1.1), 1.6 (SD 0.8) for tracer particles B80 nm and 1.3 (SD 0.5) for larger particles [7] . Colloidal tracer particles of 100-200 nm are not commercially available and currently the most widely used radiopharmaceutical in the USA is the technetium-labeled sulfur colloid in a non-filtered (with particles ranging from about 15 to 5000 nm) or filtered form.
In Europe, the majority of Nuclear Medicine Centers use human serum albumin particles of 40-100 nm (95 % \ 80 nm), whereas antimony trisulfide (range 3-30 nm) is commonly used in Australia and Canada.
With regard to the timing of preoperative scintigraphy, it should be taken into account that the amount of marked colloidal particles detectable in the SN 15-18 h after injection is low; in fact, only 1 % of the subdermally injected activity remains in the lymph node and this percentage is further reduced if the dose is administered via peritumoral injection [7] . In general, lymphoscintigraphy performed in the afternoon prior to surgery (15-18 h before surgery) leads to optimal lymphatic drainage for radiocolloids of any particle size. Conversely, if only smaller radiocolloids are available, it is better to perform the imaging study and surgical procedure on the same day to avoid the colloids draining to second-or third-echelon nodes before surgery. A colloid labeled with 99mTc is used for the ROLL technique: a review of the literature [29] reveals that macro-aggregates are the tracer of choice in about 67 % of cases and 99mTc-nanocolloids in the remaining 33 %, without, however, any difference in the detection rate of lesions during surgery.
Methods of inoculation
The optimal injection approach has been much debated over the past 18 years. The different methods proposed can be divided into two main categories: deep injection (intratumoral, peritumoral or subtumoral) and superficial (intradermal, subdermal, subareolar or periareolar). Multiple studies have been carried out to compare outcomes using the different injection methods, the majority showing equivalent rates for the detection of SN, whereas a few reported that periareolar and subareolar injections are slightly better than peritumoral injection. Only one study [30] observed a significant difference between superficial and deep injection. Two prospective randomized trials on inoculation methods have been published to date [31, 32] without, however, reaching definitive conclusions. Povoski et al. reported that the rate of identification of the SN was higher with intradermal injection, while Rodier concluded that periareolar injection was the most effective route of administration because of the 99.11 % SN detection rate and the high concordance (95.56 %) between blue dye and radiotracer. Data from a study conducted by our group [7] comparing intradermal and peritumoral injection revealed no significant differences in the SN detection rate, the only variation worthy of note being the longer time required for SN visualization by peritumoral administration.
Other factors should be considered when deciding on the injection method. One major advantage of superficial injection is that it is easy to perform and results in less interference with scintigraphic imaging. Moreover, this method does not require ultrasound guidance, even in cases of non-palpable breast cancer. Deep injections are difficult to perform in such patients and often ultrasound or stereotaxic guidance, which also facilitate the detection of extra-axillary nodes.
We believe that both deep and superficial injection approaches are valid techniques and often complementary; combinations of injection techniques (either peritumoral and subareolar/periareolar injections [33] or subdermal/ peritumoral injection [34] ) may improve detection accuracy and decrease false-negative rates (FNR). This is supported by the results from Suami et al.'s [35] human cadaver study of breast lymphatic anatomy which showed that although the majority of superficial lymph vessels of the breast drain to only one sentinel node some show alternative lymphatic drainage. Our current approach is to use subdermal injection if the tumor is localized superficially and peritumoral administration when the lesion is located deeper within the mammary gland.
Imaging
The acquisition of images after administration of the radiopharmaceutical is considered an indispensable part of the process of identification of the SN. Such images, in fact, provide basic information on pathways that are unobtainable when only the probe is used. The images acquired after the injection of the colloid greatly enhance the accuracy of the surgical resection [36] ; this is especially true when the SN is localized near the site of injection of the tracer, or when extra-axillary lymph nodes are involved, e.g. internal mammary chain (IMC) nodes. The time required to perform the preoperative scintigraphy varies on the basis of the tracer used, ranging between 15 and 90 min after injection [37] [38] [39] , while surgery can be delayed for up to 16-18 h after injection with radiocolloids of 200-1000 nm [40] .
It has been seen that both SPECT and SPECT/CT are useful in specific conditions [41] [42] [43] [44] ; EANM guidelines [45] recommend the use of tomographic imaging in cases of non-visualization of SN in planar images, especially in obese patients, in the presence of extra-axillary drainage or in sites that are difficult to visualize, e.g. multiple drainage sites, IMC nodes, intramammary lymph nodes, contralateral axilla nodes or surgically resected sites. The use of SPECT/CT is also advisable when conventional images are difficult to interpret, for example in the event of contamination or when SN is located near the site of injection.
Indications and controversies
The localization and biopsy of the SN represent the ''standard of care'' for the staging of axillary lymph nodes in breast cancer patients. These procedures have also replaced axillary lymph node dissection (ALND), performed routinely in the past, in women with stage I-II breast cancer with no evidence of axillary lymph node involvement [7, 45, 46] .
Patients with negative SN biopsy do not require ALND, as concluded by American Society of Clinical Oncology guidelines [47] on the basis of results from large randomized trials conducted in both Europe and the US [48] [49] [50] [51] [52] (Table 1) . However, ALND remains the standard treatment for patients with axillary metastases identified by SN biopsy and is also performed in cases in which the SN is not identified during surgery.
Minimal lymph node involvement
One area that requires further investigation is that of the detection of micrometastases and/or isolated tumor cells [53] .
Between 2001 and 2010, the International Breast Cancer Study Group (IBCSG) 23-01 trial recruited women with primary breast cancer B5 cm and only SN micrometastatic disease from 27 institutions. The women were randomized to SN only or standard complete ALND. At a median follow-up of 5 years, the axillary recurrence rate was \1 % in both arms and survival outcomes were similar in the ALND and SLNB-alone-groups (DFS: 84 % vs 88 %, respectively) [52] . Comparable results were obtained in the multi-institutional ACOSOG study [51] which evaluated the safety of not performing ALND in a subgroup of patients with SN-detected micrometastatic disease. Patients were randomized to either complete ALND or observation.
Results showed that there was no difference in local recurrence or disease-free survival between patients undergoing observation and ALND at a median follow-up of 6.3 years. Five-year overall survival in the axillary dissection arm was 91. The 2011 St. Gallen Consensus Conference [54] concluded that micrometastases in the SN are not an indication for ALND, irrespective of the type of breast surgery performed.
Ductal carcinoma in situ (DCIS)
DCIS metastasizes to axillary lymph nodes in a very small proportion of patients (1-2 % of cases) and for this reason the National Cancer Institute does not recommend SN biopsy [55] . However, the diagnosis of DCIS is often subject to sampling error, and a certain percentage of patients with an initial diagnosis of DCIS are actually found to have invasive carcinoma with axillary metastases after surgery. The role of SN biopsy in the management of DCIS is much debated: some authors recommend its use because of the somewhat alarming rate of diagnostic errors [56, 57] , while others advise against it on the basis of the low incidence of lymph node involvement in patients with true DCIS [58] . A meta-analysis of 22 published studies revealed that the incidence of SN metastases in patients with a preoperative diagnosis of DCIS was 7.4 % (95 % CI 6.2-8.9), significantly higher than that in patients with a definite post-operative diagnosis of DCIS (3.7 %) [59] . SN biopsy is currently recommended in patients with DCIS submitted to mastectomy; in patients in whom breast conservation is planned, SN biopsy can be performed later if invasion is detected in a surgical specimen. Nevertheless, some centers opt to perform SN biopsy in DCIS patients because they sustain that wide local excision may alter lymphatic drainage, especially to IMCs, making a subsequent SN biopsy difficult [60] .
SN biopsy after prior breast or axillary surgery
The SN method is normally restricted to women who have not already undergone surgery as it is important to have an intact lymphatic system for optimal drainage. However, there is evidence to suggest that SN biopsy can also be performed after either conservative or radical surgical treatment: Port et al. [61] , in their study of 117 patients previously submitted to surgery, reported an SN detection rate of 55 % which was directly proportional to the number of lymph nodes removed during the first intervention, and was more successful after a previous SLN biopsy than a previous ALND (74 vs. 38 %). In this series, although there were no cases of locoregional recurrence at a mean follow-up of 2.2 years, 5 % of patients developed distant recurrence. Cox et al. [62] reported an SN detection rate of 80 % in a series of 56 patients, with no axillary recurrence after 2 years. The same group subsequently published data on patients who had previously undergone ipsilateral lymph node dissection, this time reporting a detection rate of only 29 % [63] .
The experiences reported in the literature suggest that distant metastases are more frequently detected than axillary lymph node recurrence when SN biopsy is performed as second surgery, thus lessening its impact from a prognostic or therapeutic point of view.
Pregnancy
There are obvious difficulties in the management of breast cancer during pregnancy, e.g. how to evaluate nodal status. Although this was not a problem when axillary dissection was the standard staging procedure, careful assessment of the risks and benefits of the SN technique is required in this population. The technique in both melanoma and breast cancer uses a standard dose of 11-111 mBq of 99mTc-nanocolloids. In pregnant patients, the dose absorbed by the fetus is about 0.43 cGy [64] and the risk of embryonic or fetal genetic defects ranges from 0.024 to 0.099 % per cGy [65] , whereas the lowest threshold for fetal teratogenicity has been estimated at 5 cGy [66] . Although studies conducted on pregnant women [64] suggest that the radionuclide does not put the fetus at risk and that the technique can be used safely in this population, there are still too few data to confirm this. For this reason, written informed consent must be obtained from the patient before the procedure can be undertaken.
Sentinel lymph node of IMNs
The SN technique allows for a better assessment of lymph node status in IMNs which are generally evaluated in the standard surgical procedure. The presence of IMN metastases is a poor prognostic factor [67] and is correlated with a higher incidence of distant metastases and reduced survival [68, 69] . The involvement of IMNs is more frequent in tumors located in inner breast quadrants, even in cases of subcentimeter lesions. The risk of distant metastases increases by 30 % in inner quadrant lesions, with a 20 % higher mortality; in particular, the risk of metastasis to IMN is associated with age (decreases with increasing age), primary tumor size and the presence of axillary metastases [70] .
From a methodological point of view, intraparenchymal or peritumoral administration of a 0.2-0.3 ml volume of 15-18 MBq of 99mTc albumin colloids is required to visualize IMNs. This method of administration permits at least one IMN to be visualized in 60 % of tumors, whereas intra/subcutaneous administration is only effective in 1-2 % of cases. Furthermore, the probability of visualizing IMNs increases if the injection is made in the inner quadrants of the breast. However, it must be underlined that tumors located deep within the breast, especially in inner quadrants, probably drain to IMNs, making it necessary to perform lymphoscintigraphy to localize the SN [71] .
The role of IMN biopsy remains to be defined. There is some evidence that the mapping of IMNs improves staging and facilitates therapeutic decision making (radiotherapy or systemic therapy), but this has yet to be confirmed [72] .
ROLL and SNOLL
SN biopsy and ROLL can be used in combination (SNOLL) for cancers or high-grade infiltrating ductal atypia. A recent review [73] analyzed the results from seven studies evaluating 983 patients with non-palpable breast cancer. The rate of complete resection with negative margins ranged from 82 to 90.5 %, while 2-12 % of patients required re-operation.
The authors concluded that, although SNOLL is a feasible, safe and effective procedure for the treatment of nonpalpable breast cancers, multicenter randomized trials are needed to validate the methodology before it can be approved as a standard of care in this type of tumor. New non-radioactive tracers SN biopsy and ROLL/SNOLL require radioactive substances, thus restricting their use to centers with a nuclear medicine department. This limiting factor probably explains why, despite the increased incidence of breast cancer, the use of SN biopsy has reached a plateau of about 60 % in developed countries that have access to this procedure [74] , decreasing to 5 % in China and the rest of the world [75] . Recent years have seen the development of alternative methods that involve the use of non-radioactive substances. A recent systematic review by Ahmed et al. [76] analyzed 21 studies on new molecules for SN biopsy, including fluorescent indocyanine green (ICG), contrastenhanced ultrasound (CEUS) using microbubbles, or superparamagnetic iron oxide nanoparticles (SPIO). The authors concluded that the new methods were not superior to SN biopsy performed with traditional molecules in terms of the SN detection rate. Thill et al. [77] recently carried out an international prospective, multicentre, non-randomized paired equivalence study on 150 patients with histologically confirmed breast cancer to evaluate the TSentiMag Ò technique, a non-radioactive detection system that magnetically marks the location of lymph nodes prior to their surgical removal and subsequent analysis. The authors detected 291 SNs in 150 patients using both 99mTc and TsentiMag Ò ; the nodal detection rate was 91.8 % for the radioisotope and 97.3 % for the SPIO tracer, with a nodal concordance of 98.5 % (263/267; CI 96.5-99.5 %) and a reverse nodal concordance of 92.9 % (263/283; CI 89.5-95.5 %). It was concluded that magnetic SN biopsy was comparable with the standard radioactive method in terms of ease of execution, safety and efficacy. All of the new technologies require further evaluation in randomized controlled trials prior to their introduction into clinical practice.
Conclusion
SN biopsy has gradually become the standard of care for a number of solid tumors. In particular, the use of this procedure in breast cancer has greatly reduced surgical treatment-related morbidity, reducing the number of patients submitted to unnecessary axillary dissection. It is also easy to perform and safe for patients and healthcare operators.
